RxDoctor Payments Data

Jorge Asconape, MD

Neurology · Oakbrook Terrace, ILNPI 1245200609

Payments from drug & device makers

$108,750in general payments, 2019–2025

Across 130 payments — averaging $836.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$88K
  • UCB, Inc.$11K
  • UCB SA$5K
  • Eisai Inc.$3K
  • Medtronic$1K
  • Neurelis, Inc.$36
  • plus $30 from 2 others

What the payments were for

  • Consulting fees$8,2008%
  • Speaking & faculty fees$92,30085%
  • Travel & lodging$5,6175%
  • Food & beverage$2,5362%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,750 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$45,172
Medicare patients
380
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate619$979,098
BriviactBrivaracetam108$203,859
RebifInterferon Beta-1a/Albumin12$123,014
EpidiolexCannabidiol (Cbd)24$115,454
OnfiClobazam13$84,649
LamictalLamotrigine30$67,622
Lacosamide332$65,886
FycompaPerampanel27$43,932
NayzilamMidazolam28$39,593
TopamaxTopiramate12$34,100
AptiomEslicarbazepine Acetate11$34,085
VimpatLacosamide25$28,199
Levetiracetam612$22,089
Carbamazepine ErCarbamazepine82$18,718
Keppra XrLevetiracetam19$17,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$87,794$979,098619 claims
UCB, Inc.Briviact, Nayzilam, Vimpat$11,295$271,651161 claims
Eisai Inc.Fycompa$3,244$43,93227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.

Other neurology in Oakbrook Terrace

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →